- Approximately 53 Million Shares Shorted Since August 2010
- Short Squeeze Expected When Stock Crosses Above $0.22 SqueezeTrigger Price
Los Angeles, March 6, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on BioCorRx (OTC: BICX) after releasing the latest short sale data through March 5, 2015. According to the research from this provider, the total aggregate number of shares shorted since August 2010 is approximately 53 million shares and approximately 24.72% of the Company's daily trading volume since August 2010 has been short selling. The SqueezeTrigger price for all BICX shares shorted is $0.22. A short squeeze is expected to begin when shares of BICX close above the $0.22 SqueezeTrigger price. To learn more about SqueezeTrigger prices and short squeezes, visit www.buyins.net and the links immediately below.
Click here to view Report: http://www.buyins.com/reports/bicx3-5-15.pdf
Click here for SqueezeTrigger: http://www.buyins.com/images2/bicxstr3-5-15.jpg
Click here for Friction Factor: http://www.buyins.com/images2/bicxff3-5-15.jpg
Click here for detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of BICX. 37% of the previous 38 trading days have been positive or bullish-biased and 63% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Securities and Exchange Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors BICX market-makers daily for compliance with Fair Market-Making Requirements.
BUYINS.NET, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.
About BioCorRx, Inc.
BioCorRx, Inc. (R) (BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program(R) consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BUYINS.NET is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The Company has paid a non-affiliate $1,117 per month for six months of data provided in this report. BICX has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.